Research Review: September 2025

This meta-analysis has immediate practice implications: vitamin D2 is not a neutral substitute for D3 — it actively depletes D3 stores. Practitioners should review whether their clients’ supplements, fortified foods, or prescriptions contain D2 or D3, as the distinction is now clinically meaningful. This is particularly relevant for vegan and vegetarian clients who may rely on D2-fortified plant milks and foods. The recommendation is clear: preferentially use vitamin D3 (cholecalciferol) supplementation, and for vegan clients, seek out lichen-derived D3 rather than mushroom-derived D2.

This trial validates magnesium bisglycinate for sleep — but with the critical caveat that it works best in people who are magnesium-insufficient. The blanket recommendation of “take magnesium for sleep” oversimplifies. Practitioners should assess dietary magnesium intake (dark leafy greens, nuts, seeds, whole grains) before recommending supplementation, and set expectations accordingly: clients with adequate dietary magnesium intake are unlikely to notice a significant sleep benefit. This aligns with October’s COSMOS cocoa finding — supplements work best when there’s a deficit to correct.

Three practical takeaways for every practitioner who recommends adaptogens: (1) Single-ingredient standardized extracts are demonstrably safer than multi-ingredient blends — the 3.2× higher AE rate for combination products is clinically significant. (2) High-dose concentrated green tea extract requires hepatic monitoring — the hepatotoxicity signal is real. (3) The most commonly recommended adaptogens (ashwagandha, rhodiola, ginseng) have favorable clinical trial safety profiles, but practitioners should acknowledge the evidence gap for long-term use beyond 12 months. When recommending adaptogenic botanicals, specify the standardized extract, recommend single-ingredient products, and monitor for hepatic and GI adverse effects.

This study provides the mechanistic “why” behind the Mediterranean diet’s neuroprotective reputation. Polyphenol dose matters: the green-MED diet, with 3× the polyphenol load of the standard MED diet, produced the strongest brain-protective protein changes. For practitioners counseling on brain health, the recommendation goes beyond “eat Mediterranean” to “eat Mediterranean with intentional polyphenol loading” — specifically green tea, walnuts, and diverse plant-based protein sources. The identification of Gal-9 and DCN as modifiable biomarkers opens the door to tracking dietary brain protection through blood tests rather than waiting for MRI changes.

This study is hypothesis-generating, not practice-changing — yet. The 69% symptom reduction and 32% BDNF increase are compelling signals that warrant controlled follow-up. For nutrition practitioners working alongside mental health providers, the study opens a conversation about ketogenic dietary interventions as metabolic therapy for depression, particularly for clients who respond poorly to standard treatment. The rapid onset of benefit (week 2) and the BDNF mechanism distinguish this from purely behavioral dietary improvements. However, practitioners must be transparent about the limitations: no control group, small sample, concurrent medication. This is a signal, not a prescription.

This umbrella review resolves a long-standing debate: omega-3 supplementation provides a small but real cognitive benefit in adults with MCI or early decline. The practical recommendations are specific: aim for ≥1,000 mg/day total omega-3 with a DHA-dominant formulation (DHA:EPA ratio ≥3:1). The threshold effect means adequate dosing is important but mega-dosing is unnecessary. For practitioners, this supports omega-3 as one component of a multi-pronged cognitive protection strategy alongside dietary pattern optimization, exercise, and sleep — not as a standalone intervention.

This meta-analysis gives practitioners the data to personalize low-carb recommendations: moderate carbohydrate restriction is the cardiovascular sweet spot. It improves triglycerides, blood pressure, and lipid ratios with minimal LDL trade-off. Ketogenic diets should be reserved for specific therapeutic applications (epilepsy, potentially depression) where the metabolic benefits outweigh the LDL increase. The macronutrient replacement strategy matters — combined fat and protein replacement outperforms either alone. For clients with elevated triglycerides, insulin resistance, or metabolic syndrome, moderate carb restriction now has a robust evidence base across 174 RCTs.

This study positions berberine as the most evidence-based botanical for secondary colorectal cancer prevention. The finding that 2 years of supplementation provides at least 6 years of protection is extraordinary — no other botanical intervention has demonstrated this kind of durable benefit from a defined treatment course. For practitioners, this means berberine can be recommended as a time-limited intervention (2 years) for patients with a history of colorectal adenomas, with ongoing benefit expected after discontinuation. At 300 mg twice daily, the dose is well within standard clinical ranges. The durability of effect strongly suggests that berberine is not just suppressing polyp growth but fundamentally altering the colonic environment — a concept with profound implications for botanical chemoprevention.